2018 - 2023 | AHA Tobacco Regulation and Addiction Center (A-TRAC) 2.0 FDA / NHLBI U54 |
2013 - 2018 | American Heart Association Tobacco Regulation and Addiction Center (A-TRAC) NHLBI P50 HL120163-01 TCORS |
2002 - 2014 | Mapping Susceptibility Loci for Nicotine Dependence NIDA DA-12844 |
2010 - 2011 | A Second Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-aminomethylnicotine-P. aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation Nabi Biopharmaceuticals |
2008 - 2010 | Influence of Provider Individual Differences on Tobacco Treatment Training Outcomes Pfizer |
2005 - 2009 | Tobacco Cessation via Public Health Dental Clinics NCI R01 CA107442-01A2 |
2003 - 2007 | Tobacco Quitlines: Adjunct to Dental Interventions NIDA DA-017972-01 |
2004 - 2005 | Clinical Trial DRI5154 Sanofi - Synthelabo Comparison of the Efficacy and Safety of 3 Oral Doses of SSR591813L, 20 mg, 40 mg, 80 mg twice daily versus Placebo, as an Aid to Smoking Cessation. A US, Multi-Center, Randomized, Double-blind, 4-Arm, Fixed Dose, 7-Week Treatment, PHASE II Trial. |
2002 - 2005 | Clinical Trial EFC4796 Sanofi - Synthelabo Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg / day or 20 mg / day, versus Placebo, as an Aid to Maintenance of Smoking Cessation - A Multiple Country, Randomized, Double-blind, 5 Arm, Placebo-Controlled, Parallel-Group, Fixed Dose, 2-year, Multi-Center, Phase III Trial: 1-Year Treatment, 1-Year Follow-up. |
2002 - 2005 | Smoking Cessation Research in Primary Care Treatment Centers GlaxoSmithKline |
2002 - 2003 | Clinical Trial A3051018 Pfizer A Forty-Week, Double-Blind, Multicenter, Non-Treatment Study Extension to Study A3051007 Evaluating the Efficacy of Four Dosing Strategies for CP-526,555 (0.5 mg BID, titrated 0.5 mg BID, 1 mg BID and titrated 1 mg BID) in Smoking Cessation. |
2001 - 2003 | Chewer's Choice NCI |
2001 - 2002 | Clinical Trial A3051007 Pfizer A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of Four Dosing Strategies for CP-526,555 (0.5 mg BID, titrated 0.5 mg BID, 1 mg BID and titrated 1 mg BID) in Smoking Cessation. |
1999 - 2002 | Guideline Implementation for Tobacco Study Veterans Affairs HSR&D |